Status:
COMPLETED
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
HIV Vaccine Trials Network
Pharmexa-Epimmune
Conditions:
HIV Infections
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.
Detailed Description
The worldwide HIV/AIDS epidemic may only be controlled through the development of a safe and effective vaccine that will prevent HIV infection. DNA-based vaccines alone promote a weak immune response ...
Eligibility Criteria
Inclusion
- Good general health
Exclusion
- Previous receipt of smallpox vaccination
- HIV-infected
- Hepatitis B surface antigen positive
- Participation in prior HIV vaccination trial
- Immunosuppressive medications within 168 days prior to study entry
- Receipt of blood products within 120 days of study entry
- Receipt of live attenuated, medically indicated subunit, or killed (inactivated) vaccines within 30 days of study entry
- Certain abnormal lab values
- Pregnant or breastfeeding
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00428337
Start Date
April 1 2007
End Date
August 1 2008
Last Update
October 14 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco Vaccine and Prevention CRS
San Francisco, California, United States, 94102
2
Univ. of Rochester HVTN CRS
Rochester, New York, United States, 14642
3
Vanderbilt Vaccine CRS
Nashville, Tennessee, United States, 37232